BSc(Hons) PhD FCAHS
Professor and Dean
Dr. Michael Coughtrie is professor and dean at the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC). Born in Glasgow, Scotland, he received his BSc in biochemistry in 1983 and PhD in 1986 from the University of Dundee where he also began his professional teaching and research career based in the School of Medicine there. In 2003, Dr. Coughtrie was awarded a Personal Chair in Biochemical Pharmacology and became head of the Division of Pathology and Neuroscience. In 2008, he assumed the role of director, Division of Medical Sciences and in 2011 he accepted the appointment of operations director of the Medical Research Institute.
Dr. Coughtrie commenced his term as dean of the UBC Faculty of Pharmaceutical Sciences on August 1, 2013. His extensive teaching experience encompasses the development and implementation of a number of course modules in the fields of medicine, dentistry and science. As a researcher focusing on the roles of two major families of drug metabolizing enzymes, he has supervised numerous PhD and postdoctoral students, been invited to speak at over 70 international meetings and conferences, and has received more than 70 competitive research grants and contracts. In addition, Dean Coughtrie is an accomplished author, having written more than 200 papers, articles, book chapters, and abstracts appearing in publications such as The Biochemical Journal, The New England Journal of Medicine, The Journal of Biological Chemistry and Drug Metabolism & Disposition.
Throughout his career, Dr. Coughtrie has volunteered his significant senior management experience and passion for the pharmaceutical sciences to a number of different boards, committees and professional associations and serves on the editorial boards of publications including Pharmacogenetics & Genomics, Xenobiotica and Biomarkers.
Dr. Coughtrie's research program is directed towards understanding the role of conjugation and transport in drug metabolism, and in the homeostasis of important endogenous compounds such as steroids, thyroid hormones and bilirubin. The main focus has been on the enzyme families sulfotransferases and UDP-glucuronosyltransferases, and he has carried out some of the seminal work that has guided our understanding of the role these enzymes play during human development. Another major interest is in the role that sulfation of glycosaminoglycans, which are important molecules that govern the interaction of cells with each other and their environment, plays in cancer.
"Assessment and Validation of In Vitro Systems for Evaluating Drug Metabolic Pathways Involving Glucuronidation and Sulfation." Coughtrie M (PI), with Pfizer. $185,000. Biotechnology & Biological Sciences Research Council. 2009–2013.
"Enzymatic Synthesis of Glucuronides." Coughtrie M (co-PI), with Novacta Biosystems. $970,000. Engineering and Physical Sciences Research Council. 2007–2012.
“SNAP Trial: Double-Blind, Randomised, Placebo-Controlled Trial of Nicotine Replacement Therapy in Pregnancy.” Coleman T (PI), Coughtrie M, and six others. $2.8M. 2006–2011.
"Conference Chair." Coughtrie M. International Workshop on Conjugation. Vancouver, BC. September 2016.
“Advances in Conjugative Metabolism: From Molecules to Populations – Session Chair and Discussion Leader.” Coughtrie M. Gordon Research Conference on Drug Metabolism. Plymouth, NH. July 2015.
"Role of Sulfation in Drug Metabolism." Coughtrie M. UK Drug Metabolism Discussion Group. Dundee, UK. June 2013.
"Conference Chair." Coughtrie M. 11th European ISSX Meeting. Lisbon, PT. May 2009.